- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- he NICE-Wide Prioritisation Board met on 15 September 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. The board concluded that the clear rationale to not evaluate this product is due to it being a reformulation of hydrocortisone, with modified release mechanism. Modified-release hydrocortisone is recommended in current clinical guideline NG243 Overview | Adrenal insufficiency: identification and management | Guidance | NICE for this indication. Therefore, a NICE evaluation is not likely to add any further value to the system. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12254
Email enquiries
If you have any queries please email [email protected]
Related links
For further information on how we select topics for development, please see our page about prioritising our guidance topics